Start with its own history
At 28.18×, APNHY is 60.9% above its 9-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.
OTC · APNHYDrug Manufacturers - Specialty & GenericUpdated Nov 4, 2026
Aspen Pharmacare Holdings Limited P/E ratio
Current valuation, historical context, and peer comparisons.
Current P/E ratio
28.18×
60.9% abovethe 9-observation annual average
Share price10.04
÷Earnings per share0.3563
Price and EPS in quote currency. Calculation details
Investors are paying 28.18 for every 1 of reported earnings per share.
P/E over time
2017 – 2026
Annual P/ESelected-period average 17.52×
3-year average24.68×2 positive annual observations
5-year average18.67×4 positive annual observations
10-year average17.52×9 positive annual observations
Peer median · TTM28.50×6 peers with positive P/E
Historical P/E ratios
Annual period-end data · 17 observations
| Period end | P/E | Change |
|---|---|---|
| Jun 30, 2026 | 26.32× | N/M |
| Jun 30, 2025 | N/M | N/M |
| Jun 30, 2024 | 23.04× | +47.7% |
| Jun 30, 2023 | 15.60× | +60.6% |
| Jun 30, 2022 | 9.71× | -42.1% |
| Jun 30, 2021 | 16.78× | +24.4% |
| Jun 30, 2020 | 13.49× | +82.5% |
| Jun 30, 2019 | 7.39× | -62.3% |
View all 17 annual observations +
| Period end | P/E | Change |
|---|---|---|
| Jun 30, 2018 | 19.61× | -23.7% |
| Jun 30, 2017 | 25.70× | -33.0% |
| Jun 30, 2016 | 38.34× | +21.4% |
| Jun 30, 2015 | 31.58× | +16.0% |
| Jun 30, 2014 | 27.22× | -6.3% |
| Jun 30, 2013 | 29.04× | +49.1% |
| Jun 30, 2012 | 19.48× | +38.2% |
| Jun 30, 2011 | 14.09× | -8.3% |
| Jun 30, 2010 | 15.37× | N/M |
Change is relative to the preceding observation. N/M values are excluded from averages.
How APNHY compares
Company P/E vs. peer trailing-12-month ratios
| Company | P/E ratio |
|---|---|
 APNHY This stockAspen Pharmacare Holdings Limited | 28.18× |
 AMRXAmneal Pharmaceuticals, Inc. | 46.40× |
 HKMPYHikma Pharmaceuticals PLC | 13.28× |
 TEVATeva Pharmaceutical Industries Limited | 93.00× |
 VTRSViatris Inc. | N/M |
 BHCBausch Health Companies Inc. | N/M |
 AMPHAmphastar Pharmaceuticals, Inc. | 16.10× |
 ANIPANI Pharmaceuticals, Inc. | 14.83× |
 RDYDr. Reddy's Laboratories Limited | 40.89× |
Peers are selected by the data provider. Business models and earnings definitions can differ.
Put the numbers in context
What does APNHY’s P/E tell you?
Compare like with like
The median of the 6 positive peer ratios above is 28.50×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.
Check what drives earnings
One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.
Keep your research connected
Take APNHY into your spreadsheet
Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.
Explore WisesheetsQuarterly P/E · latest quarterLQ selects the latest reported quarter. Requires the Wisesheets add-in. See available data
=WISE("APNHY", "PE Ratio", "LQ")Sources & calculation methodology
Current P/E
Share price 10.04 ÷ EPS 0.3563 = 28.18×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Nov 4, 2026; this is not a real-time trading quote.
History & averages
Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.
Data definitions and limitations
The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.
APNHY P/E ratio: common questions
The essentials behind the numbers.
Aspen Pharmacare Holdings Limited's current P/E is 28.18× based on the quote data last updated Nov 4, 2026. It represents the share price divided by reported earnings per share. Prices and earnings may refresh on different schedules.
Annual P/E uses earnings for a completed fiscal year. Trailing-12-month (TTM) P/E uses the latest four quarters, while forward P/E uses forecast earnings. These are not interchangeable. This page labels peer ratios as TTM and shows dated annual or quarterly historical observations; it does not show forward estimates.
N/M means not meaningful: the feed has no positive P/E for that observation. Negative or zero earnings should not be ranked as a low positive valuation multiple. N/M observations are excluded from the averages shown above.
Divide the share price by earnings per share (EPS). For example, a share price of 100 and EPS of 5 gives a P/E of 20×. This page uses the price and EPS supplied together in the quote when both are positive.
Price timestamps, EPS definitions, share classes, adjustments, and fiscal periods can differ. A forward P/E also uses forecast earnings rather than reported earnings. Compare the inputs and as-of dates before comparing two displayed ratios.
Not necessarily. The average describes previous market pricing, not fair value. Changes in earnings quality, growth expectations, debt, accounting, and business risk can justify a different multiple today.